# US 2002/0058615 A1 · Endothelial specific targeting

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058615 A1
- Document ID: US20020058615A1
- Status: Published application
- Kind: A1
- Application number: 09/810,700
- Filed: 2001-03-16
- Published: 2002-05-16
- Earliest claimed: 2000-03-16
- Assignees: University of Pittsburgh
- Inventors: Michael K. Wong; Ruth A. Modzelewski; Charles Komen Brown; Candace S. Johnson; Donald L. Trump
- Web page: https://patentgrep.com/patent/US20020058615A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Peptide motifs which define specificity of tumor-derived endothelial cells. These peptides possess a charge motif of positive-positive-hydrophobic which is important in determining the specificity of binding to tumor-derived endothelium. The specific molecular peptide motifs will facilitate diverse therapeutic and diagnostic applications including: anti-angiogenic therapies to be used in alone or in conjunction with standard therapies; imaging tools for both detection of very small metastasis that are undetectable by current techniques; for monitoring tumor response; for targeting and directing chemotherapy drugs to the tumor; for treatment of chronic inflammatory diseases such as rheumatoid arthritis and psoriasis, for treating some forms of blindness; as well as other diagnostic and therapeutic applications.

## Claims

### Claim 1

A purified peptide fragment with selective binding to tumor-derived endothelial cells, wherein the peptide fragment possesses a charge motif of positive- positive- neutral hydrophobic (++).

### Claim 2 (depends on 1)

The purified peptide fragment of claim 1, wherein the peptide fragment is not greater than fifty amino acid residues in length.

### Claim 3 (depends on 1)

The purified peptide fragment of claim 1, wherein said peptide is operatively attached to a therapeutic agent capable of exerting a cytotoxic effect on a tumor.

### Claim 4 (depends on 1)

The purified peptide fragment of claim 1, formulated as a pharmaceutical composition.

### Claim 5 (depends on 3)

The purified peptide fragment of claim 3, wherein the peptide attached to a therapeutic agent is capable of exerting a cytotoxic effect on tumor vasculature sufficient to lead to tumor necrosis.

### Claim 6 (depends on 1)

The purified peptide fragment of claim 1, wherein said peptide fragment is linked to a diagnostic agent that is detectable upon imaging.

### Claim 7

A composition useful for targeting tumor-derived endothelial cells, said composition comprising a peptide selected from the group consisting essentially of SEQ ID NO 1 Cys-Gly-Gly-Arg-His-Ser-Gly-Gly-Cys; SEQ ID NO 2 Cys-Gly-Gly-Arg-Lys-Leu-Gly-Gly-Cys; SEQ ID NO 3 Cys-Gly-GlyArg-Arg-Leu-Gly-Gly-Cys; SEQ ID NO 4 Cys-Gly-Gly-Arg-Arg-Ser-Arg-Gly-Gly-Cys; and SEQ ID NO 5 Cys-Leu-Leu-Arg-Arg-Ser-Arg-Leu-Leu-Cys.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said peptide is capable of being operatively attached to a therapeutic agent that is capable of exerting a cytotoxic effect on tumor vasculature.

### Claim 9 (depends on 7)

The composition of claim 7, wherein said peptide is operatively attached to a therapeutic agent capable of exerting a cytotoxic effect on tumor vasculature.

### Claim 10 (depends on 7)

The composition of claim 7, wherein said peptide is capable of being operatively attached to a therapeutic agent capable of exerting a cytotoxic effect on a tumor.

### Claim 11 (depends on 7)

The composition of claim 7, wherein the therapeutic agent includes at least one agent selected from the group consisting essentially of anticellular agents, chemotherapeutic agents, radioisotopes, and cytotoxins.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the therapeutic agent is an anticellular agent and said anticellular agent comprises a steroid, an antimetabolite, an anthracycline, a vinca alkaloid, an antibiotic, an alkylating agent, or an epipodophyllotoxin.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the therapeutic agent is an anticellular agent and said anticellular agent comprises a plant-, fungus- or bacteria-derived toxin.

### Claim 14 (depends on 11)

The composition of claim 11, wherein said therapeutic agent is a cytotoxin and said cytotoxin comprises an A chain toxin, a ribosome inactivating protein, gelonin, .alpha.-sarcin, aspergillin, restrictocin, a ribonuclease, diphthia toxin, Pseudomonas exotoxin, a bacterial endotoxin, or the lipid A moiety of a bacterial endotoxin.

### Claim 15 (depends on 7)

The composition of claim 7, formulated as a pharmaceutical composition.

### Claim 16 (depends on 9)

The composition of claim 9, wherein the peptide attached to a therapeutic agent is capable of exerting a cytotoxic effect on tumor vasculature sufficient to lead to tumor necrosis.

### Claim 17 (depends on 7)

The purified peptide fragment of claim 7, wherein said peptide is linked to a diagnostic agent that is detectable upon imaging.

### Claim 18 (depends on 17)

The composition of claim 17, wherein said diagnostic agent is selected from the group consisting of paramagnetic ions, radioactive ions and fluorogenic ions detectable upon imaging.

### Claim 19 (depends on 18)

The composition of claim 18, wherein said diagnostic agent is a paramagnetic ion, and said paramagnetic ion is selected from the group consisting essentially of chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) and erbium (III).

### Claim 20 (depends on 18)

The composition of claim 18, wherein said diagnostic agent is a radioactive ion, and said radioactive ion is selected from the group consisting essentially of iodine123, technetium99m, indium111, rhenium188, rhenium186, copper67, iodine131, yttrium90, iodine125, astatine211, and gallium67.

### Claim 21

A method for treating a diseased state in a mammal comprising: administering an effective amount of a peptide fragment with selective binding to tumor-derived endothelial cells, wherein the peptide fragment possesses a charge motif of positive-positive-neutral hydrophobic (++).

### Claim 22 (depends on 21)

The method of claim 21, wherein the diseased state includes chronic inflammatory diseases.
